Log in

IVERIC bio Stock Forecast, Price & News

+0.41 (+8.33 %)
(As of 09/28/2020 06:00 AM ET)
Today's Range
Now: $5.33
50-Day Range
MA: $4.85
52-Week Range
Now: $5.33
Volume771,800 shs
Average Volume779,327 shs
Market Capitalization$477.05 million
P/E RatioN/A
Dividend YieldN/A
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ISEE



Sales & Book Value

Annual Sales$209.98 million
Book Value$2.82 per share


Net Income$-58,860,000.00


Market Cap$477.05 million
Next Earnings Date11/10/2020 (Estimated)
+0.41 (+8.33 %)
(As of 09/28/2020 06:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ISEE News and Ratings via Email

Sign-up to receive the latest news and ratings for ISEE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

IVERIC bio (NASDAQ:ISEE) Frequently Asked Questions

How has IVERIC bio's stock been impacted by COVID-19?

IVERIC bio's stock was trading at $4.46 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ISEE shares have increased by 19.5% and is now trading at $5.33.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of IVERIC bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IVERIC bio

When is IVERIC bio's next earnings date?

IVERIC bio is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for IVERIC bio

How were IVERIC bio's earnings last quarter?

IVERIC bio Inc (NASDAQ:ISEE) issued its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.01.
View IVERIC bio's earnings history

What price target have analysts set for ISEE?

3 brokers have issued 12-month target prices for IVERIC bio's stock. Their forecasts range from $13.00 to $13.00. On average, they expect IVERIC bio's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 143.9% from the stock's current price.
View analysts' price targets for IVERIC bio

Are investors shorting IVERIC bio?

IVERIC bio saw a increase in short interest in September. As of September 15th, there was short interest totaling 2,890,000 shares, an increase of 13.3% from the August 31st total of 2,550,000 shares. Based on an average daily volume of 945,900 shares, the days-to-cover ratio is presently 3.1 days.
View IVERIC bio's Short Interest

Who are some of IVERIC bio's key competitors?

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO), Opko Health (OPK), Tesla (TSLA), Exxon Mobil (XOM) and Agile Therapeutics (AGRX).

Who are IVERIC bio's key executives?

IVERIC bio's management team includes the following people:
  • Dr. David R. Guyer, Exec. Chairman (Age 59)
  • Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 63)
  • Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 58)
  • Mr. David F. Carroll, Sr. VP, CFO & Treasurer (Age 53)
  • Mr. Keith Westby M.B.A., Sr. VP & COO (Age 44)

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

Who are IVERIC bio's major shareholders?

IVERIC bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include RTW Investments LP (12.85%), Deerfield Management Company L.P. Series C (11.23%), Perceptive Advisors LLC (3.89%), Orbimed Advisors LLC (6.33%), Versant Venture Management LLC (3.36%) and Logos Global Management LP (1.75%). Company insiders that own IVERIC bio stock include David Francis Carroll, David R Guyer, Glenn Sblendorio and Keith Westby.
View institutional ownership trends for IVERIC bio

Which institutional investors are selling IVERIC bio stock?

ISEE stock was sold by a variety of institutional investors in the last quarter, including PDT Partners LLC, Jane Street Group LLC, and Schonfeld Strategic Advisors LLC. Company insiders that have sold IVERIC bio company stock in the last year include David R Guyer, and Keith Westby.
View insider buying and selling activity for IVERIC bio

Which institutional investors are buying IVERIC bio stock?

ISEE stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, Deerfield Management Company L.P. Series C, Orbimed Advisors LLC, Perceptive Advisors LLC, Versant Venture Management LLC, Logos Global Management LP, Goldman Sachs Group Inc., and Nuveen Asset Management LLC.
View insider buying and selling activity for IVERIC bio

How do I buy shares of IVERIC bio?

Shares of ISEE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $5.33.

How big of a company is IVERIC bio?

IVERIC bio has a market capitalization of $477.05 million and generates $209.98 million in revenue each year. The company earns $-58,860,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. IVERIC bio employs 35 workers across the globe.

What is IVERIC bio's official website?

The official website for IVERIC bio is ivericbio.com.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The company can be reached via phone at 212-845-8200 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.